$GANX: Gain Therapeutics, Inc. Reports Second Quarter 2021
$GANX: Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update
Click here:
https://www.globenewswire.com/news-release/20...pdate.html
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx(TM) target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.For more information, please visit https://www.gaintherapeutics.com
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...
Continue Reading
A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...
Continue Reading
A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...
Continue Reading
A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...
Continue Reading
Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...
Continue Reading
Top 5 Most Recently Viewed Articles
Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...
Continue Reading
Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...
Continue Reading
Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...
Continue Reading
Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...
Continue Reading
The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...
Continue Reading